Cargando…
Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology
Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-se...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420051/ https://www.ncbi.nlm.nih.gov/pubmed/14975041 http://dx.doi.org/10.1186/cc2338 |
_version_ | 1782121460046757888 |
---|---|
author | Holmes, Cheryl L Landry, Donald W Granton, John T |
author_facet | Holmes, Cheryl L Landry, Donald W Granton, John T |
author_sort | Holmes, Cheryl L |
collection | PubMed |
description | Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-sensitive K(+ )channels, nitric oxide pathways, and interaction with adrenergic agents. We explore the complex and contradictory studies of vasopressin on cardiac inotropy and coronary vascular tone. Finally, we summarize the clinical studies of vasopressin in shock states, which to date have been relatively small and have focused on physiologic outcomes. Because of potential adverse effects of vasopressin, clinical use of vasopressin in vasodilatory shock should await a randomized controlled trial of the effect of vasopressin's effect on outcomes such as organ failure and mortality. |
format | Text |
id | pubmed-420051 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-4200512004-06-04 Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology Holmes, Cheryl L Landry, Donald W Granton, John T Crit Care Review Vasopressin is emerging as a rational therapy for vasodilatory shock states. In part 1 of the review we discussed the structure and function of the various vasopressin receptors. In part 2 we discuss vascular smooth muscle contraction pathways with an emphasis on the effects of vasopressin on ATP-sensitive K(+ )channels, nitric oxide pathways, and interaction with adrenergic agents. We explore the complex and contradictory studies of vasopressin on cardiac inotropy and coronary vascular tone. Finally, we summarize the clinical studies of vasopressin in shock states, which to date have been relatively small and have focused on physiologic outcomes. Because of potential adverse effects of vasopressin, clinical use of vasopressin in vasodilatory shock should await a randomized controlled trial of the effect of vasopressin's effect on outcomes such as organ failure and mortality. BioMed Central 2004 2003-06-26 /pmc/articles/PMC420051/ /pubmed/14975041 http://dx.doi.org/10.1186/cc2338 Text en Copyright © 2004 BioMed Central Ltd |
spellingShingle | Review Holmes, Cheryl L Landry, Donald W Granton, John T Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology |
title | Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology |
title_full | Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology |
title_fullStr | Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology |
title_full_unstemmed | Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology |
title_short | Science Review: Vasopressin and the cardiovascular system part 2 – clinical physiology |
title_sort | science review: vasopressin and the cardiovascular system part 2 – clinical physiology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420051/ https://www.ncbi.nlm.nih.gov/pubmed/14975041 http://dx.doi.org/10.1186/cc2338 |
work_keys_str_mv | AT holmescheryll sciencereviewvasopressinandthecardiovascularsystempart2clinicalphysiology AT landrydonaldw sciencereviewvasopressinandthecardiovascularsystempart2clinicalphysiology AT grantonjohnt sciencereviewvasopressinandthecardiovascularsystempart2clinicalphysiology |